SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Eddy D, Johnston C, Cummings SR, Dawson-Hughes B, Lindsay R, Melton LJ, Slemenda CW 1998 Osteoporosis: Review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis. Osteoporos Int 8 (Suppl 4): S7S80.
  • 2
    Cummings SR, Black DM, Nevitt MC, Browner W, Cauley J, Ensrud K, Genant HK, Palermo L, Scott J, Vogt TM 1993 Bone density at various sites for prediction of hip fractures. Lancet 341: 7275.
  • 3
    Marshall D, Johnell O, Wedel H 1996 Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312: 12541259.
  • 4
    Cummings SR, Palermo L, Browner W, Marcus R, Wallace R, Pearson J, Blackwell T, Eckert S, Black D 2000 Monitoring osteoporosis therapy with bone densitometry: Misleading changes and regression to the mean. Fracture Intervention Trial Research Group. JAMA 283: 13181321.
  • 5
    Cummings SR, Parfitt AM 2001 Bone density regression to the mean and the individual patient. J Clin Endocrinol Metab 86: 40014002.
  • 6
    Bonnick SL 2000 Monitoring osteoporosis therapy with bone densitometry: A vital tool or regression toward mediocrity? J Clin Endocrinol Metab 85: 34933495.
  • 7
    Delmas PD 2000 How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis? Bone 27: 13.
  • 8
    Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM 2002 Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med 112: 281289.
  • 9
    Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD 2002 Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab 87: 15861592.
  • 10
    Wasnich RD, Miller PD 2000 Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab 85: 231236.
  • 11
    Garnero P, Hausherr E, Chapuy MC, Marcell C, Grandjean H, Muller C, Cormier C, Breart G, Meunier PJ, Demas PD 1996 Markers of bone resorption predict hip fracture in elderly women: The EPIDOS prospective study. J Bone Miner Res 11: 15311538.
  • 12
    van Daele PLA, Seibel MJ, Burger H, Hofman A, Grobbee DE, van Leeuwen JPTM, Birkenhäger JC, Pols HAP 1996 Case-control analysis of bone resorption markers, disability, and hip fracture risk: The Rotterdam Study. BMJ 312: 482483.
  • 13
    Ross PD, Kress BC, Parson RE, Wasnich RD, Armour KA, Mizrahi IA 2000 Serum bone alkaline phosphatase and calcaneus bone density predict fractures: A prospective study. Osteoporos Int 11: 7682.
  • 14
    Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD 2000 Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study. J Bone Miner Res 15: 15261536.
  • 15
    Looker AC, Bauer DC, Chesnut CH III, Gundberg CM, Hochberg MC, Klee G, Kleerekoper M, Watts NB, Bell NH 2000 Clinical use of biochemical markers of bone remodeling: Current status and future directions. Osteoporos Int 11: 467480.
  • 16
    Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J 2000 The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 11 (Suppl 6): S2S17.
  • 17
    Bjarnason NH, Sarkar S, Duong T, Mitlak B, Delmas PD, Christiansen C 2001 Six and twelve month changes in bone turnover are related to reduction in vertebral fracture risk during 3 years of raloxifene treatment in postmenopausal osteoporosis. Osteoporos Int 12: 922930.
  • 18
    Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD 2003 Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res 18: 10511056.
  • 19
    Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ 1998 Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: Results from the Fracture Intervention Trial. JAMA 280: 20772082.
  • 20
    Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE 1996 Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348: 15351541.
  • 21
    Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Nevitt MC, Suryawanshi S, Cummings SR 2000 Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85: 41184124.
  • 22
    Black DM, Reiss TF, Nevitt MC, Cauley J, Karpf D, Cummings SR 1993 Design of the Fracture Intervention Trial. Osteoporos Int 3 (Suppl 3): S29S39.
  • 23
    Garnero P, Delmas PD 1993 Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease. J Clin Endocrinol Metab 77: 10461053.
  • 24
    Rosenquist C, Fledelius C, Christgau S, Pedersen BJ, Bonde M, Qvist P, Christiansen C 1998 Serum CrossLaps One Step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen. Clin Chem 44: 22812289.
  • 25
    Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A, Risteli J 1996 Immunoassay for intact amino-terminal propeptide of human type I procollagen. Clin Chem 46: 947954.
  • 26
    Black DM, Thompson DE, Bauer DC, Ensrud K, Musliner T, Hochberg MC, Neuitt MC, Suryawanshi S, Cummings SR 2000 Fracture risk reduction with alendronate in women with osteoporosis: The Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab 85: 41184124.
  • 27
    Genant HK, Wu CY, van Kuijk C, Nevitt MC 1993 Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8: 11371148.
  • 28
    Clowes JA, Eastell R 2000 The role of bone turnover markers and risk factors in the assessment of osteoporosis and fracture risk. Baillieres Best Pract Res Clin Endocrinol Metab 14: 213232.
  • 29
    Eastell R 1996 Assessment of bone density and bone loss. Osteoporos Int 6 (Suppl 2): 35.
  • 30
    Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C 2002 Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): Effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 31: 5761.
  • 31
    Bjarnason NH, Henriksen EE, Alexandersen P, Christgau S, Henriksen DB, Christiansen C 2002 Mechanism of circadian variation in bone resorption. Bone 30: 307313.
  • 32
    Chapurlat RD, Garnero P, Breart G, Meunier PJ, Delmas PD 2000 Serum type I collagen breakdown product (serum CTX) predicts hip fracture risk in elderly women: The EPIDOS study. Bone 27: 283286.
  • 33
    Hochberg MC, Ross PD, Black D, Cummings SR, Genant HK, Nevitt MC, Barrett-Connor E, Musliner T, Thompson D 1999 Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. Fracture Intervention Trial Research Group. Arthritis Rheum 42: 12461254.
  • 34
    Riggs BL, Melton LJ III 2002 Bone turnover matters: The raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density. J Bone Miner Res 17: 114.
  • 35
    Bruyere O, Collette J, Delmas P, Rouillon A, Roux C, Seidel L, Richy F, Reginster JY 2003 Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women. Maturitas 44: 259265.
  • 36
    Seibel MJ, Naganathan V, Barton I, Grauer A 2004 Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate. J Bone Miner Res 19: 323329.